Plus Therapeutics’ Rhenium Nanoliposomes are fast tracked in glioblastoma Sep. 15, 2020 By Lee Landenberger No Comments The FDA has granted Plus Therapeutics Inc. fast track designation for its lead candidate, Rhenium Nanoliposomes (RNL), for treating recurrent glioblastoma, propelling it into the sixth cohort of a phase I dose-finding trial.Read More